Research topics:
The Laboratory of Immunology at MMRI PAS focuses on elucidating the mechanisms regulating immune cell activation and advancing cancer immunotherapy using monoclonal antibodies, effector cells and cells modified with chimeric antigen receptors (CAR). Our work ranges from basic research in the field of cancer immunology to translational research aimed at improving the efficacy of cancer therapy.

Bajor lab

PI: Małgorzata Bajor PhD - head of laboratory

tel. +48 22 60 86 516; email:  This email address is being protected from spambots. You need JavaScript enabled to view it., room: A106a

Scientific research:
In recent years, dynamic development of immunotherapeutic strategies in the treatment of cancer has been observed. Immunotherapy works by stimulating the body's immune system to fight cancer cells. Despite numerous attempts and successes in this field, immunotherapy still encounters many obstacles in the effective elimination of cancer cells. One of the reasons for the failure of therapeutic strategies is the unfavorable, immunosuppressive tumor microenvironment (TME). Various components of the TME exert harmful and inhibitory effects on the migration and effector functions of immune cells and their ability to infiltrate the tumor. One of the research projects carried out by our team is the phenomenon of ferroptosis and its significance in the context of the activity of immune cells in immunosuppressive TME. Ferroptosis is a regulated cell death characterized by iron-dependent increased lipid peroxidation. The aim of our research is to elucidate the role of ferroptosis in activated T cells and its potential impact on the effectiveness of immunotherapy based on T cells modified with chimeric antigen receptor (CAR) (OPUS 17 project). In addition, we conduct research aimed at understanding the mechanisms of the immunosuppressive effect of the tumor microenvironment and to develop a therapeutic approach that will improve the anticancer activity of immunotherapy by targeting this microenvironment. In our study, we hypothesized that the elimination of cells present in the TME, for example, tumor-associated macrophages, would increase the efficacy of the immune response against tumor cells (OPUS 23 project).

Team members:

Małgosia Bajor

Research workers:

Marta Kłopotowska PhD; tel. +48 22 60 86 477, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A104

Master's students:

Natalia Leśniowska

Students:

 Anna Jurga, Szymon Hajduk

 Winiarska Lab

PI: Magdalena Winiarska, PhD
tel. +48 22 60 86 574; email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A108a

Scientific research

Team members

Magda Winiarska

Senior researchers:

Agnieszka Graczyk-Jarzynka, PhD; tel. +48 22 60 86 516, email This email address is being protected from spambots. You need JavaScript enabled to view it. room: A106a
Iwona Baranowska, PhD; tel. +48 22 60 86 595, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A109

PhD students:

Marta Krawczyk  MSc; tel. +48 22 60 86 477, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A104
Monika Granica, MSc
Aleksandra Kusowska, MSc
Andryi Zhylko, MD

Students:

Milena Dziewicka, Magdalena Justyniarska, Gustaw Laskowski

Technician:   

 Ewa Pięta

Firczuk Lab

PI: Małgorzata Firczuk, PhD
tel. +48 22 60 86 449; email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A107a

Scientific research:
Our research focuses on better understanding the genetic, metabolic and antigenic differences between cancer cells and normal cells. Our goal is to develop new, targeted therapies for cancer, especially therapies directed against hematological malignancies. Additionally, we are developing in vitro and in vivo models to test the effectiveness of innovative immunotherapies and other targeted therapies in preclinical studies.

Team members

Małgosia Firczuk

PhD students: Krzysztof Domka MD; tel. +48 60 86 582, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A108

Students: Agnieszka Dąbkowska, tel. +48 22 60 86 582, room A108
Julia Grzybowska, Kaja Tyszkiewicz, Weronika Zając

Rygiel lab

PI: Tomasz Rygiel, PhD
tel. +48 22 60 86 449; email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A107a

Scientific research
Our research focuses on understanding the role of the tumor microenvironment in cancer progression. A large number of untransformed cells develop within the tumor, which has a significant impact on the dynamics of cancer cells' growth and spread. These cells, in combination with extracellular factors such as extracellular matrix proteins, secretory factors, and metabolites, create a complex and dynamic tumor microenvironment. Interactions between this microenvironment and cancer cells influence many tumor characteristics, including response to chemotherapy, immunotherapy, and metastatic potential.

Our research team focuses on exploiting the tumor microenvironment for cancer therapy. We are particularly interested in repolarizing cancer macrophages to switch their function to inhibit tumor growth. This would be useful for developing novel strategies for the targeted delivery of therapeutic agents that would activate the immune system to fight cancer. We are also investigating innovative cell therapies based on macrophage drug conjugate (MDC). Furthermore, we are collaborating with other research groups to develop new diagnostic technologies, such as fiber-optic detectors of inflammatory factors, and to investigate a novel mechanism of free hemoglobin uptake by liver endothelial cells, that may be important for the development of new therapies.

Team members:

Tomasz Rygiel

Research workers

 Agata Braniewska, PhD; tel. +48 22 60 86 477, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A104

PhD students:

 MSc Marcin Skórzyński; tel. +48 22 60 86 477, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A104

Students:

 Michał Nizio, Oliwia Woźniak

 


Laboratory Coordinator: Magdalena Banach-Orłowska, PhD
tel. +48 22 60 86 595, email: This email address is being protected from spambots. You need JavaScript enabled to view it., room A109


Former employees and co-workers:

  • Łukasz Komorowski, PhD, currently post-doc at The Hospital for Sick Children, Toronto, Canada
  • Martyna Janowska, PhD researcher at Celon Pharma S.A.
  • dr Tomasz Grzywa, MD PhD currently post-doc at The Children's Hospital of Philadelphia, USA

Student Scientific Association of Immunooncology under the supervision of Laboratory of Immunology

Supervisor of the Association: Magdalena Winiarska PhD This email address is being protected from spambots. You need JavaScript enabled to view it.
President of the Association: Anna Jurga  This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it. 
http://stn.wum.edu.pl/kola-naukowe/skn-immunoonkologii

Activities at the Association include acquisition of theoretical knowledge and laboratory skills as part of research projects conducted in the laboratory. Students are the co-authors of numerous presentations at scientific conferences, scientific publications and they are beneficiaries of student mini-grants. It is possible to carry out summer internships and prepare bachelor's, engineering and master's theses as part of the activities of the Laboratory of Immunology. We invite students of biology, biotechnology, medicine and related fields of study who complete their degrees at universities in Warsaw (WUM, UW, SGGW, PW and others) to join our Association of Immunooncology.

Scientific projects in progress

  • Exploring kinase hyperactivation as an innovative approach for chemo-immunotherapy for B cell acute lymphoblastic leukemia; PI: Małgorzata Firczuk PhD; PRELUDIUM BIS NCN (2024-2028)
  • Unraveling protease activation in stimulated CAR-T cells to identify new biomarkers for assessing their clinical efficacy; PI: Małgorzata Firczuk PhD; OPUS NCN. (2024-2028)
  • Unveiling the molecular signature underlying resistance to CD19 CAR-T therapy in malignant cells. PI: Marta Krawczyk MSc; PRELUDIUM NCN. (2024-2027)
  • Bottom-up manufacturing of artificial anti-tumor T cells.
    The project is conducted in consortium with the Catholic University of Louvain (Leader), the Tuscan Life Sciences Foundation, and the University Hospital of Groningen. PI in MMRI PAS Małgorzata Firczuk PhD; EIC PATHFINDER. (2024-2029)
  • Depletion of the tumor microenvironment as a novel strategy potentiating the efficacy of immunotherapies. PI: Małgorzata Bajor PhD; OPUS NCN (2023-2027)
  • Investigation of the role of complement in shaping resistance to NK-cell cytotoxicity. PI: Aleksandra Kusowska MSc; PRELUDIUM NCN. (2023-2025)
  • Identification of surface proteins as alternate targets for CAR-T therapy against CD19-negative tumors PI: Magdalena Winiarska PhD; PRELUDIUM BIS NCN. (2021-2025)
  • Searching for novel strategies improving cancer immunotherapy (STIMUNO). PI: Magdalena Winiarska PhD, ERC Starting Grant. (2019-2025)
  • Delivery of immuno-activators to phagocytic cells in order to obtain an antitumor response PI: Tomasz Rygiel PhD; OPUS NCN (2021-2025).
  • Optical fiber biosensing systems for fast and early identification of inflammatory factors PI in MMRI PAS: Tomasz Rygiel PhD; OPUS NCN. (2020-2024)
  • Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies. PI: Agnieszka Graczyk-Jarzynka PhD; SONATA NCN
  • Improving therapeutic efficacy of anti-CD20 antibodies in precursor B-cell acute lymphoblastic leukemia. PI: Małgorzata Firczuk PhD; OPUS NCN. (2020-2024).
  • The role of the oxidative stress in adoptive cell therapy with chimeric antigen receptors PI: Małgorzata Bajor PhD; OPUS NCN (2020-2024)

Finished projects:

  • Identification of novel therapies potentiating the efficacy of immunotherapy with anti-CD20 antibodies in in vivo models. PI: Magdalena Winiarska PhD; SONATA BIS NCN (2016-2023)

Scientific techniques:

  • genetic engineering (modulation of gene expression: shRNA, siRNA, sgRNA, gene overexpression, construction of synthetic receptors)
  • isolation of primary effector cells from healthy donors and cancer patients
  • genetic modifications of cells by viral and non-viral vectors expression of intracellular and membrane proteins
  • flow cytometry-based analyses
  • evaluation of cellular cytotoxicity in vitro and activity of CAR-modified cells
  • evaluation of the effectiveness of therapies in vivo

Equipment:

  • Cytometry laboratory: flow cytometer BD FACSCanto™ II, flow cytometer BD FACSCanto™ II with HTS module
  • Cell culture room: clean bench for two people. (2x), CO2 incubator, centrifuge
  • Biochemistry laboratory: equipment for electrophoresis and Western Blotting
  • Genetic engineering laboratory: nanodrop, Qubit fluorimeter, Bio-Rad​ thermocycler, equipment for electrophoresis of nucleic acids, clean bench for work with DNA/RNA
  • BSL2 Laboratory​: clean bench for 2 people, CO2 incubator, centrifuge, Inverted Fluorescence Microscope Zeiss with camera
  • Others: Ultra-low freezer -80, nitrogen tank

National cooperation:

  • Medical University of Warsaw
  • Institute of Hematology and Transfusion Medicine, Warsaw
  • Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw
  • International Institute of Molecular and Cellular Biology, Warsaw
  • Medical University of Lodz
  • Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw
  • University of Warsaw
  • Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw
  • Wroclaw University of Technology
  • Warsaw University of Life Sciences
  • Warsaw University of Technology

International cooperation:

  • Oslo University Hospital, Norway
  • Vrije University Medical Centre, Amsterdam, The Netherlands
  • Toscana Life Sciences Foundation, Siena, Italy
  • International Centre for Genetic Engineering and Biotechnology, Triest, Italy
  • University of Oxford, The United Kingdom
  • University Medical Center Utrecht, The Netherlands
  • Catholic University of Leuven, Belgium
  • University Hospital Groningen, The Netherlands

Selected publications:

2023

  • Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S. Efficient chimeric antigen receptor targeting of a central epitope of CD22. J Biol Chem. 2023 Jul;299(7):104883. doi: 10.1016/j.jbc.2023.104883.https://pubmed.ncbi.nlm.nih.gov/37269947/

2022

  • Kubacz M, Kusowska A, Winiarska M, Bobrowicz M. In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies. Cancers (Basel). 2022 Dec 30;15(1):235. doi: 10.3390/cancers15010235. https://pubmed.ncbi.nlm.nih.gov/36612228/
  • Zagozdzon R, Winiarska M, Firczuk M. Immune Evasion as the Main Challenge for Immunotherapy of Cancer. Cancers (Basel). 2022 Jul 26;14(15):3622. doi: 10.3390/cancers14153622  https://www.mdpi.com/2072-6694/14/15/3622
  • Marhelava K, Krawczyk M, Firczuk M, Fidyt K. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. Cells. 2022 May 31;11(11):1804. doi: 10.3390/cells11111804. https://pubmed.ncbi.nlm.nih.gov/35681499/
  • Fidyt K, Pastorczak A, Cyran J, Crump NT, Goral A, Madzio J, Muchowicz A, Poprzeczko M, Domka K, Komorowski L, Winiarska M, Harman JR, Siudakowska K, Graczyk-Jarzynka A, Patkowska E, Lech-Maranda E, Mlynarski W, Golab J, Milne TA, Firczuk M. Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. Oncogene. 2022 Mar;41(11):1600-1609. doi: 10.1038/s41388-022-02196-y. https://www.nature.com/articles/s41388-022-02196-y
  • Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci. 2022 Mar 29;23(7):3778. doi: 10.3390/ijms23073778. https://pubmed.ncbi.nlm.nih.gov/35409139/
  • Goral A, Firczuk M, Fidyt K, Sledz M, Simoncello F, Siudakowska K, Pagano G, Moussay E, Paggetti J, Nowakowska P, Gobessi S, Barankiewicz J, Salomon-Perzynski A, Benvenuti F, Efremov DG, Juszczynski P, Lech-Maranda E, Muchowicz A. A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia. Front Immunol. 2022 Feb 28;13:781364. doi:10.3389/fimmu.2022.781364. https://pubmed.ncbi.nlm.nih.gov/35296093/
  • Niziolek M, Bicka M, Osinka A, Samsel Z, Sekretarska J, Poprzeczko M, Bazan R, Fabczak H, Joachimiak E, Wloga D. PCD Genes-From Patients to Model Organisms and Back to Humans. Int J Mol Sci. 2022 Feb 3;23(3):1749. doi: 10.3390/ijms23031749. https://pubmed.ncbi.nlm.nih.gov/35163666/
  • Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, Zhylko A, Soroczynska K, Retecki K, Krawczyk M, Klopotowska M, Pilch Z, Paczek L, Malmberg KJ, Wälchli S, Winiarska M, Zagozdzon R. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022 Jan;10(1):e002500. doi: 10.1136/jitc-2021-002500. https://pubmed.ncbi.nlm.nih.gov/35078921/
  • Kusowska A, Kubacz M, Krawczyk M, Slusarczyk A, Winiarska M, Bobrowicz M. Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. Int J Mol Sci. 2022 Jan 28;23(3):1501. doi: 10.3390/ijms23031501. https://www.mdpi.com/1422-0067/23/3/1501

2021:

  • Klopotowska, M., Bajor, M., Graczyk-Jarzynka, A., Kraft, A., Pilch, Z., Zhylko, A., Firczuk, M., Baranowska, I., Lazniewski, M., Plewczynski, D., Goral, A., Soroczynska, K., Domagała, J., Marhelava, K., Slusarczyk, A., Retecki, K., Ramji, K., Krawczyk, M., Temples, M.N., Sharma, B., Lachota, M., Netskar, H., Malmberg, K.-J., Zagozdzon, R., Winiarska, M., 2021. PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. Cancer Immunol Res. https://doi.org/10.1158/2326-6066.CIR-20-1023
  • Retecki, K., Seweryn, M., Graczyk-Jarzynka, A., Bajor, M., 2021. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel) 13. https://doi.org/10.3390/cancers13236012
  • Szydłowski, M., Garbicz, F., Jabłońska, E., Górniak, P., Komar, D., Pyrzyńska, B., Bojarczuk, K., Prochorec-Sobieszek, M., Szumera-Ciećkiewicz, A., Rymkiewicz, G., Cybulska, M., Statkiewicz, M., Gajewska, M., Mikula, M., Gołas, A., Domagała, J., Winiarska, M., Graczyk-Jarzynka, A., Białopiotrowicz, E., Polak, A., Barankiewicz, J., Puła, B., Pawlak, M., Nowis, D., Golab, J., Tomirotti, A.M., Brzózka, K., Pacheco-Blanco, M., Kupcova, K., Green, M.R., Havranek, O., Chapuy, B., Juszczyński, P., 2021. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res 81, 6029–6043. https://doi.org/10.1158/0008-5472.CAN-21-1023
  • Miazek-Zapala, N., Slusarczyk, A., Kusowska, A., Zapala, P., Kubacz, M., Winiarska, M., Bobrowicz, M., 2021. The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 10. https://doi.org/10.3390/cells10061511
  • Cendrowicz, E., Sas, Z., Bremer, E., Rygiel, T.P., 2021. The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel) 13. https://doi.org/10.3390/cancers13081946
  • Pastorczak, A., Domka, K., Fidyt, K., Poprzeczko, M., Firczuk, M., 2021. Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia. Cancers (Basel) 13. https://doi.org/10.3390/cancers13071536
  • Sosnowska, A., Chlebowska-Tuz, J., Matryba, P., Pilch, Z., Greig, A., Wolny, A., Grzywa, T.M., Rydzynska, Z., Sokolowska, O., Rygiel, T.P., Grzybowski, M., Stanczak, P., Blaszczyk, R., Nowis, D., Golab, J., 2021. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. Oncoimmunology 10, 1956143. https://doi.org/10.1080/2162402X.2021.1956143
  • Tonecka, K., Braniewska, A., Pilch, Z., Sas, Z., Skorzynski, M., Manuali, E., Rygiel, T.P., 2021. The CD200 Regulates Inflammation in Mice Independently of TNF-α Production. Int J Mol Sci 22. https://doi.org/10.3390/ijms22105358

2020:

  • Bajor, M., Graczyk-Jarzynka, A., Marhelava, K., Kurkowiak, M., Rahman, A., Aura, C., Russell, N., Zych, A.O., Firczuk, M., Winiarska, M., Gallagher, W.M., Zagozdzon, R., 2020. Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells. Antioxidants (Basel) 9. https://doi.org/10.3390/antiox9040320
  • Białopiotrowicz, E., Noyszewska-Kania, M., Kachamakova-Trojanowska, N., Łoboda, A., Cybulska, M., Grochowska, A., Kopczyński, M., Mikula, M., Prochorec-Sobieszek, M., Firczuk, M., Graczyk-Jarzynka, A., Zagożdżon, R., Ząbek, A., Młynarz, P., Dulak, J., Górniak, P., Szydłowski, M., Pyziak, K., Martyka, J., Sroka-Porada, A., Jabłońska, E., Polak, A., Kowalczyk, P., Szumera-Ciećkiewicz, A., Chapuy, B., Rzymski, T., Brzózka, K., Juszczyński, P., 2020. Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. Cancers (Basel) 12. https://doi.org/10.3390/cancers12030580
  • Bobrowicz, M., Kubacz, M., Slusarczyk, A., Winiarska, M., 2020a. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies. Int J Mol Sci 21. https://doi.org/10.3390/ijms21249531
  • Bobrowicz, M., Slusarczyk, A., Domagala, J., Dwojak, M., Ignatova, D., Chang, Y.-T., Iselin, C., Miazek-Zapala, N., Marhelava, K., Guenova, E., Winiarska, M., 2020b. Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors. Oncol Lett 20, 533–540. https://doi.org/10.3892/ol.2020.11587
  • Domagala, J., Lachota, M., Klopotowska, M., Graczyk-Jarzynka, A., Domagala, A., Zhylko, A., Soroczynska, K., Winiarska, M., 2020. The Tumor Microenvironment-A Metabolic Obstacle to NK Cells’ Activity. Cancers (Basel) 12. https://doi.org/10.3390/cancers12123542
  • Domka, K., Goral, A., Firczuk, M., 2020. cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies. Front Immunol 11, 1538. https://doi.org/10.3389/fimmu.2020.01538
  • Firczuk, M., Bajor, M., Graczyk-Jarzynka, A., Fidyt, K., Goral, A., Zagozdzon, R., 2020. Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Lett 471, 1–11. https://doi.org/10.1016/j.canlet.2019.11.037
  • Kiraga, Ł., Cerutti, G., Braniewska, A., Strzemecki, D., Sas, Z., Boffi, A., Savino, C., Montemiglio, L.C., Turnham, D., Seaton, G., Bonamore, A., Clarkson, R., Dabkowski, A.M., Paisey, S.J., Taciak, B., Kucharzewska, P., Rygiel, T.P., Król, M., 2020. Biodistribution PET/CT Study of Hemoglobin-DFO-(89)Zr Complex in Healthy and Lung Tumor-Bearing Mice. Int J Mol Sci 21. https://doi.org/10.3390/ijms21144991
  • Komorowski, L., Fidyt, K., Patkowska, E., Firczuk, M., 2020. Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. Int J Mol Sci 21. https://doi.org/10.3390/ijms21165776
  • Lachota, M., Vincenti, M., Winiarska, M., Boye, K., Zagożdżon, R., Malmberg, K.-J., 2020. Prospects for NK Cell Therapy of Sarcoma. Cancers (Basel) 12. https://doi.org/10.3390/cancers12123719
  • Wachowska, M., Stachura, J., Tonecka, K., Fidyt, K., Braniewska, A., Sas, Z., Kotula, I., Rygiel, T.P., Boon, L., Golab, J., Muchowicz, A., 2020. Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. Cancer Immunol Immunother 69, 1101–1112. https://doi.org/10.1007/s00262-020-02528-5
  • Zhylko, A., Winiarska, M., Graczyk-Jarzynka, A., 2020. The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers (Basel) 12. https://doi.org/10.3390/cancers12082030

2019:

  • Bobrowicz, M., Zagozdzon, R., Domagala, J., Vasconcelos-Berg, R., Guenova, E., Winiarska, M., 2019. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. Cancers (Basel) 11. https://doi.org/10.3390/cancers11101420
  • Czystowska-Kuzmicz, M., Sosnowska, A., Nowis, D., Ramji, K., Szajnik, M., Chlebowska-Tuz, J., Wolinska, E., Gaj, P., Grazul, M., Pilch, Z., Zerrouqi, A., Graczyk-Jarzynka, A., Soroczynska, K., Cierniak, S., Koktysz, R., Elishaev, E., Gruca, S., Stefanowicz, A., Blaszczyk, R., Borek, B., Gzik, A., Whiteside, T., Golab, J., 2019. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun 10, 3000. https://doi.org/10.1038/s41467-019-10979-3
  • Fidyt, K., Pastorczak, A., Goral, A., Szczygiel, K., Fendler, W., Muchowicz, A., Bartlomiejczyk, M.A., Madzio, J., Cyran, J., Graczyk-Jarzynka, A., Jansen, E., Patkowska, E., Lech-Maranda, E., Pal, D., Blair, H., Burdzinska, A., Pedzisz, P., Glodkowska-Mrowka, E., Demkow, U., Gawle-Krawczyk, K., Matysiak, M., Winiarska, M., Juszczynski, P., Mlynarski, W., Heidenreich, O., Golab, J., Firczuk, M., 2019. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. Mol Oncol 13, 1180–1195. https://doi.org/10.1002/1878-0261.12476
  • Graczyk-Jarzynka, A., Goral, A., Muchowicz, A., Zagozdzon, R., Winiarska, M., Bajor, M., Trzeciecka, A., Fidyt, K., Krupka, J.A., Cyran, J., Szczygiel, K., Efremov, D.G., Gobessi, S., Jagielski, A., Siudakowska, K., Bobrowicz, M., Klopotowska, M., Barankiewicz, J., Malenda, A., Lech-Maranda, E., Miazek-Zapala, N., Skarzynski, P.H., Domagala, A., Golab, J., Firczuk, M., 2019a. Inhibition of thioredoxin-dependent H(2)O(2) removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biol 21, 101062. https://doi.org/10.1016/j.redox.2018.11.020
  • Graczyk-Jarzynka, A., Sobiak, B., Mlącki, M., Wilanowski, T., Leśniak, W., 2019b. S100A6 activates EGFR and its downstream signaling in HaCaT keratinocytes. J Cell Physiol 234, 17561–17569. https://doi.org/10.1002/jcp.28379
  • Marhelava, K., Pilch, Z., Bajor, M., Graczyk-Jarzynka, A., Zagozdzon, R., 2019. Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers (Basel) 11. https://doi.org/10.3390/cancers11111756
  • Pilch, Z., Tonecka, K., Skorzynski, M., Sas, Z., Braniewska, A., Kryczka, T., Boon, L., Golab, J., Meyaard, L., Rygiel, T.P., 2019a. The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. PLoS One 14, e0210796. https://doi.org/10.1371/journal.pone.0210796
  • Rywik, T.M., Braniewska, A., Kowalik, I., Firczuk, M., Kozar-Kamińska, K., Wojciechowska, A., Kasprzyk-Pawelec, A., Sobieszczańska-Małek, M., Leszek, P., Rozentryt, P., Zieliński, T., 2019. Fluctuations in circulating endothelial progenitor cell levels and acute cardiac graft rejection. Pol Arch Intern Med 129, 889–897. https://doi.org/10.20452/pamw.15072
  • Sasi, B.K., Martines, C., Xerxa, E., Porro, F., Kalkan, H., Fazio, R., Turkalj, S., Bojnik, E., Pyrzynska, B., Stachura, J., Zerrouqi, A., Bobrowicz, M., Winiarska, M., Priebe, V., Bertoni, F., Mansouri, L., Rosenquist, R., Efremov, D.G., 2019. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia 33, 2416–2428. https://doi.org/10.1038/s41375-019-0442-8
  • Wolosz, D., Walczak, A., Szparecki, G., Dwojak, M., Winiarska, M., Wolinska, E., Gornicka, B., 2019. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma. Eur J Histochem 63. https://doi.org/10.4081/ejh.2019.2981

2018:

  • Bajor, M., Zych, A.O., Graczyk-Jarzynka, A., Muchowicz, A., Firczuk, M., Trzeciak, L., Gaj, P., Domagala, A., Siernicka, M., Zagozdzon, A., Siedlecki, P., Kniotek, M., O’Leary, P.C., Golab, J., Zagozdzon, R., 2018. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer 119, 873–884. https://doi.org/10.1038/s41416-018-0263-y
  • Burdzinska, A., Dybowski, B., Zarychta-Wiśniewska, W., Kulesza, A., Butrym, M., Zagozdzon, R., Graczyk-Jarzynka, A., Radziszewski, P., Gajewski, Z., Paczek, L., 2018a. Intraurethral co-transplantation of bone marrow mesenchymal stem cells and muscle-derived cells improves the urethral closure. Stem Cell Res Ther 9, 239. https://doi.org/10.1186/s13287-018-0990-2
  • Burdzinska, A., Dybowski, B., Zarychta-Wiśniewska, W., Kulesza, A., Hawryluk, J., Graczyk-Jarzynka, A., Kaupa, P., Gajewski, Z., Paczek, L., 2018b. Limited accuracy of transurethral and periurethral intrasphincteric injections of cellular suspension. Neurourol Urodyn 37, 1612–1622. https://doi.org/10.1002/nau.23522
  • Calisti, L., Trabuco, M.C., Boffi, A., Testi, C., Montemiglio, L.C., des Georges, A., Benni, I., Ilari, A., Taciak, B., Białasek, M., Rygiel, T., Król, M., Baiocco, P., Bonamore, A., 2018. Engineered ferritin for lanthanide binding. PLoS One 13, e0201859. https://doi.org/10.1371/journal.pone.0201859
  • Chlebowska-Tuz, J., Sokolowska, O., Gaj, P., Lazniewski, M., Firczuk, M., Borowiec, K., Sas-Nowosielska, H., Bajor, M., Malinowska, A., Muchowicz, A., Ramji, K., Stawinski, P., Sobczak, M., Pilch, Z., Rodziewicz-Lurzynska, A., Zajac, M., Giannopoulos, K., Juszczynski, P., Basak, G.W., Plewczynski, D., Ploski, R., Golab, J., Nowis, D., 2018. Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica 103, 1843–1852. https://doi.org/10.3324/haematol.2018.190231
  • Domagala, A., Fidyt, K., Bobrowicz, M., Stachura, J., Szczygiel, K., Firczuk, M., 2018a. Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. Int J Mol Sci 19. https://doi.org/10.3390/ijms19082256
  • Domagala, A., Stachura, J., Gabrysiak, M., Muchowicz, A., Zagozdzon, R., Golab, J., Firczuk, M., 2018b. Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. BMC Cancer 18, 210. https://doi.org/10.1186/s12885-018-4126-y
  • Kiraga, Ł., Cheda, Ł., Taciak, B., Różańska, K., Tonecka, K., Szulc, A., Kilian, K., Górka, E., Rogulski, Z., Rygiel, T.P., Król, M., 2018. Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. PLoS One 13, e0206706. https://doi.org/10.1371/journal.pone.0206706
  • Oei, V.Y.S., Siernicka, M., Graczyk-Jarzynka, A., Hoel, H.J., Yang, W., Palacios, D., Almåsbak, H., Bajor, M., Clement, D., Brandt, L., Önfelt, B., Goodridge, J., Winiarska, M., Zagozdzon, R., Olweus, J., Kyte, J.-A., Malmberg, K.-J., 2018. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res 6, 467–480. https://doi.org/10.1158/2326-6066.CIR-17-0207
  • Pilch, Z., Tonecka, K., Braniewska, A., Sas, Z., Skorzynski, M., Boon, L., Golab, J., Meyaard, L., Rygiel, T.P., 2018. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Cancer Immunol Res 6, 930–940. https://doi.org/10.1158/2326-6066.CIR-17-0454
  • Pyrzynska, B., Dwojak, M., Zerrouqi, A., Morlino, G., Zapala, P., Miazek, N., Zagozdzon, A., Bojarczuk, K., Bobrowicz, M., Siernicka, M., Machnicki, M.M., Gobessi, S., Barankiewicz, J., Lech-Maranda, E., Efremov, D.G., Juszczynski, P., Calado, D., Golab, J., Winiarska, M., 2018. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology 7, e1423183. https://doi.org/10.1080/2162402X.2017.1423183
  • Taciak, B., Białasek, M., Braniewska, A., Sas, Z., Sawicka, P., Kiraga, Ł., Rygiel, T., Król, M., 2018. Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages. PLoS One 13, e0198943. https://doi.org/10.1371/journal.pone.0198943
  • Tak, T., Rygiel, T.P., Karnam, G., Bastian, O.W., Boon, L., Viveen, M., Coenjaerts, F.E., Meyaard, L., Koenderman, L., Pillay, J., 2018. Neutrophil-mediated Suppression of Influenza-induced Pathology Requires CD11b/CD18 (MAC-1). Am J Respir Cell Mol Biol 58, 492–499. https://doi.org/10.1165/rcmb.2017-0021OC
  • Zych, A.O., Bajor, M., Zagozdzon, R., 2018. Application of Genome Editing Techniques in Immunology. Arch Immunol Ther Exp (Warsz) 66, 289–298. https://doi.org/10.1007/s00005-018-0504-z

2017:

  • Bobrowicz, M., Dwojak, M., Pyrzynska, B., Stachura, J., Muchowicz, A., Berthel, E., Dalla-Venezia, N., Kozikowski, M., Siernicka, M., Miazek, N., Zapala, P., Domagala, A., Bojarczuk, K., Malenda, A., Barankiewicz, J., Graczyk-Jarzynka, A., Zagozdzon, A., Gabrysiak, M., Diaz, J.-J., Karp, M., Lech-Maranda, E., Firczuk, M., Giannopoulos, K., Efremov, D.G., Laurenti, L., Baatout, D., Frenzel, L., Malinowska, A., Slabicki, M., Zenz, T., Zerrouqi, A., Golab, J., Winiarska, M., 2017. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 130, 1628–1638. https://doi.org/10.1182/blood-2016-08-736066
  • Graczyk-Jarzynka, A., Zagozdzon, R., Muchowicz, A., Siernicka, M., Juszczynski, P., Firczuk, M., 2017. New insights into redox homeostasis as a therapeutic target in B-cell malignancies. Curr Opin Hematol 24, 393–401. https://doi.org/10.1097/MOH.0000000000000351
  • Lechowicz, U., Gambin, T., Pollak, A., Podgorska, A., Stawinski, P., Franke, A., Petersen, B.-S., Firczuk, M., Oldak, M., Skarzynski, H., Ploski, R., 2017. Iterative Sequencing and Variant Screening (ISVS) as a novel pathogenic mutations search strategy - application for TMPRSS3 mutations screen. Sci Rep 7, 2543. https://doi.org/10.1038/s41598-017-02315-w
  • Pingwara, R., Witt-Jurkowska, K., Ulewicz, K., Mucha, J., Tonecka, K., Pilch, Z., Taciak, B., Zabielska-Koczywas, K., Mori, M., Berardozzi, S., Botta, B., Rygiel, T.P., Krol, M., 2017. Interferon lambda 2 promotes mammary tumor metastasis via angiogenesis extension and stimulation of cancer cell migration. J Physiol Pharmacol 68, 573–583.
  • Winiarska, M., Nowis, D., Firczuk, M., Zagozdzon, A., Gabrysiak, M., Sadowski, R., Barankiewicz, J., Dwojak, M., Golab, J., 2017. Selection of an optimal promoter for gene transfer in normal B cells. Mol Med Rep 16, 3041–3048. https://doi.org/10.3892/mmr.2017.6974